| Pair Name | Nobiletin, Bicalutamide | ||
| Phytochemical Name | Nobiletin (PubChem CID: 72344 ) | ||
| Anticancer drug Name | Bicalutamide (PubChem CID: 2375 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Nobiletin, Bicalutamide | |||
| Disease Info | [ICD-11: 2C82.0] | Prostate cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | MAPK1 | hsa5594 |
| Down-regulation | Expression | STAT3 | hsa6774 | |
| Down-regulation | Expression | NFKB1 | hsa4790 | |
| In Vitro Model | VCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_2235 |
| PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 | |
| Result | NBT and BCT combination reduced key cellular signaling regulators including: p-Erk/Erk, p-STAT3/STAT3 and NF-κB. Overall, these results suggest that NBT combination with BCT may be an effective treatment for prostate cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Nobiletin, a citrus polymethoxyflavone, enhances the effects of bicalutamide on prostate cancer cells via down regulation of NF-κB, STAT3, and ERK activation. RSC Adv. 2020 Mar 10;10(17):10254-10262. doi: 10.1039/c9ra10020b. | Click |
